Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 6:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 73 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stable Coronary Artery Disease CAD Clear all
Completed No phase listed Observational

Evaluation of a Novel Non-Invasive Automated Fractional Flow Reserve Software System in Patients With Coronary Artery Disease

NCT06183294
View directory record Official record
Conditions
Stable Angina, Unstable Angina, NSTEMI
Interventions
Collecting invasive FFR measurements.
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Phase 3 Interventional Results available

A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

NCT00658515
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
Dalcetrapib (RO4607381), Evidence-based medical care for Acute Coronary Syndrome, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
45 Years and older
Enrollment
15,871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
513
States / cities
Birmingham, Alabama • Mobile, Alabama • Tuscaloosa, Alabama + 400 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Sep 29, 2026, 6:59 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Gene Therapy for the Treatment of Chronic Stable Angina

NCT01002495
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
VM202
Biological
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
21 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 29, 2026, 6:59 PM EDT
Completed No phase listed Observational

Angina Prevalence and Provider Evaluation of Angina Relief

NCT01705054
View directory record Official record
Conditions
Stable Coronary Artery Disease CAD
Interventions
Not listed
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
1,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Sep 29, 2026, 6:59 PM EDT
Terminated Phase 4 Interventional

Rosiglitazone and Metformin: Outcomes Trial in Nondiabetic Patients With Stable Coronary Syndromes (Romance) Pilot Study

NCT00343395
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
AVANDAMET
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Mar 16, 2011 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Not applicable Interventional Results available

FAME II - Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Treatment (OMT) Verses OMT

NCT01132495
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Stenting plus OMT, OMT, Standard of care
Other
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
21 Years and older
Enrollment
1,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
6
States / cities
Palo Alto, California • Stanford, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2019 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Phase 4 Interventional Results available

A Pharmacodynamic Study With Ticagrelor in Hispanic Patients

NCT01523366
View directory record Official record
Conditions
Stable Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Los Angeles, California • Hollywood, Florida • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Not applicable Interventional Results available

Comparative Effectiveness of Decision Aids for Stable Chest Discomfort

NCT02652208
View directory record Official record
Conditions
Coronary Artery Disease, Stable Angina
Interventions
Online decision aid, Video decision aid
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Phase 4 Interventional Results available

Direct Renin Inhibition Effects on Atherosclerotic Biomarkers

NCT00818779
View directory record Official record
Conditions
Coronary Artery Disease, Type 2 Diabetes Mellitus
Interventions
Aliskiren, Amlodipine
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Not applicable Interventional Results available

PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease

NCT03168776
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
BuMA Supreme DES, Xience or Promus DES
Device
Lead sponsor
Sino Medical Sciences Technology Inc.
Industry
Eligibility
20 Years and older
Enrollment
1,629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
40
States / cities
Birmingham, Alabama • Gilbert, Arizona • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy

NCT00984802
View directory record Official record
Conditions
Stable Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CMX-2043, Placebo control
Drug
Lead sponsor
Ischemix, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Worcester, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2011 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders

NCT00642811
View directory record Official record
Conditions
Stable Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel, Aspirin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Jonesboro, Arkansas • Ormond Beach, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Sep 29, 2026, 6:59 PM EDT
Recruiting Phase 4 Interventional

Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention

NCT06228456
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor 60mg, Clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Not applicable Interventional

Readiness for Behavior Change After a Heart Attack

NCT01596036
View directory record Official record
Conditions
Myocardial Infarction, Stable Angina, Coronary Artery Disease
Interventions
Early appointment (within 10 days), Routine referral (at 5 weeks)
Behavioral · Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 13, 2012 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Phase 4 Interventional Results available

Prasugrel/Clopidogrel Maintenance Dose Washout Study

NCT01014624
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 74 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
La Jolla, California • Jacksonville, Florida • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Sep 29, 2026, 6:59 PM EDT
Terminated Phase 4 Interventional

Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention

NCT01464671
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Bivalirudin, Heparin
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Not applicable Interventional

RecoveryPlus Telerehab Platform Pilot Study

NCT05804500
View directory record Official record
Conditions
Heart Diseases, Angina, Stable, Angina Pectoris, Myocardial Ischemia, Myocardial Infarction, Coronary Artery Disease, Coronary Artery Stenosis, Valve Heart Disease, Valve Disease, Heart
Interventions
Cardiac Telerehabilitation (CTR) via the RecoveryPlus platform
Behavioral
Lead sponsor
NODEHealth Foundation
Other
Eligibility
45 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Sep 29, 2026, 6:59 PM EDT
Not listed Phase 4 Interventional

Etomidate Versus Propofol in CABG Surgery

NCT06068764
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Etomidate, Propofol
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Sep 29, 2026, 6:59 PM EDT
Completed No phase listed Observational

Validation of the MedHub AutocathFFR Software Device for Non-Invasive Fractional Flow Reserve (FFR)

NCT07763769
View directory record Official record
Conditions
Coronary Artery Disease, Stable Angina, Unstable Angina, Non-ST-Elevation Myocardial Infarction
Interventions
MedHub AutocathFFR
Device
Lead sponsor
Medhub Ltd.
Industry
Eligibility
23 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Gainesville, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Phase 2 Interventional

Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease

NCT01058018
View directory record Official record
Conditions
Atherosclerosis, Coronary Artery Disease
Interventions
RVX000222, Placebo
Drug
Lead sponsor
Resverlogix Corp
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2023 · Synced Sep 29, 2026, 6:59 PM EDT
Active, not recruiting Not applicable Interventional

MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation

NCT05933083
View directory record Official record
Conditions
Myocardial Infarction, Heart Failure, Systolic, Heart Valve Diseases, Angina, Stable, Coronary Artery Disease, Heart Transplant
Interventions
In-person cardiac rehabilitation, Telehealth cardiac rehabilitation
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
San Francisco, California • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 29, 2026, 6:59 PM EDT
Completed No phase listed Observational

FAME II-10-year Follow-Up

NCT06159231
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
CoreAalst BV
Industry
Eligibility
21 Years and older
Enrollment
888 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Stanford, California • Decatur, Georgia • Bangor, Maine
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 29, 2026, 6:59 PM EDT
Terminated Not applicable Interventional Results available

Randomized Evaluation of Patients With Stable Angina Comparing Diagnostic Examinations

NCT01262625
View directory record Official record
Conditions
Chest Pain, Stable Angina Pectoris, CCS Class I to III, Angina Equivalent, Coronary Artery Disease
Interventions
CCTA, SPECT MPI/ICA
Device
Lead sponsor
American College of Radiology
Other
Eligibility
40 Years and older
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Decatur, Georgia • Detroit, Michigan • Salem, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Sep 29, 2026, 6:59 PM EDT
Completed Phase 3 Interventional

Trial of Lycopene/Ateronon for Secondary Prevention of Coronary Heart Disease

NCT00939237
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
Ateronon, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Sep 29, 2026, 6:59 PM EDT